tetano
Editor, Senior Moderator
J Antimicrob Chemother
. 2020 Aug 19;dkaa332.
doi: 10.1093/jac/dkaa332. Online ahead of print.
Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial
Hamideh Abbaspour Kasgari[SUP] 1 [/SUP], Siavash Moradi[SUP] 2 [/SUP], Amir Mohammad Shabani[SUP] 1 [/SUP], Farhang Babamahmoodi[SUP] 3 [/SUP], Ali Reza Davoudi Badabi[SUP] 3 [/SUP], Lotfollah Davoudi[SUP] 3 [/SUP], Ahmad Alikhani[SUP] 3 [/SUP], Akbar Hedayatizadeh Omran[SUP] 4 [/SUP], Majid Saeedi[SUP] 5 [/SUP], Shahin Merat[SUP] 6 [/SUP], Hannah Wentzel[SUP] 7 [/SUP], Anna Garratt[SUP] 8 [/SUP], Jacob Levi[SUP] 9 [/SUP], Bryony Simmons[SUP] 10 [/SUP], Andrew Hill[SUP] 11 [/SUP], Hafez Tirgar Fakheri[SUP] 12 [/SUP]
Affiliations
Abstract
Background: New therapeutic options are urgently needed to tackle the novel coronavirus disease 2019 (COVID-19). Repurposing existing pharmaceuticals provides an immediate treatment opportunity. We assessed the efficacy of sofosbuvir and daclatasvir with ribavirin for treating patients with COVID-19.
Methods: This was a single-centre, randomized controlled trial in adults with moderate COVID-19 admitted to the Ghaem Shahr Razi Hospital in Mazandaran Province, Iran. Patients were randomly assigned to 400 mg sofosbuvir, 60 mg daclatasvir and 1200 mg ribavirin (intervention group) or to standard care (control group). The primary endpoint of this study was length of hospital stay. This study is registered by IRCT.ir under the ID: IRCT20200328046886N1.
Results: Between 20 March 2020 and 8 April 2020, 48 patients were recruited; 24 patients were randomly assigned to the intervention group and 24 to the control group. The median duration of hospital stay was 6 days in both groups (P = 0.398). The number of ICU admissions in the sofosbuvir/daclatasvir/ribavirin group was not significantly lower than the control group (0 versus 4, P = 0.109). There was no difference in the number of deaths between the groups (0 versus 3, P = 0.234). The cumulative incidence of recovery was higher in the sofosbuvir/daclatasvir/ribavirin arm (Gray's P = 0.033).
Conclusions: This randomized trial was too small to make definitive conclusions. There were trends in favour of the sofosbuvir/daclatasvir/ribavirin arm for recovery and lower death rates. However, there was an imbalance in the baseline characteristics between the arms. Larger randomized trials should be conducted to investigate this treatment further.
. 2020 Aug 19;dkaa332.
doi: 10.1093/jac/dkaa332. Online ahead of print.
Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial
Hamideh Abbaspour Kasgari[SUP] 1 [/SUP], Siavash Moradi[SUP] 2 [/SUP], Amir Mohammad Shabani[SUP] 1 [/SUP], Farhang Babamahmoodi[SUP] 3 [/SUP], Ali Reza Davoudi Badabi[SUP] 3 [/SUP], Lotfollah Davoudi[SUP] 3 [/SUP], Ahmad Alikhani[SUP] 3 [/SUP], Akbar Hedayatizadeh Omran[SUP] 4 [/SUP], Majid Saeedi[SUP] 5 [/SUP], Shahin Merat[SUP] 6 [/SUP], Hannah Wentzel[SUP] 7 [/SUP], Anna Garratt[SUP] 8 [/SUP], Jacob Levi[SUP] 9 [/SUP], Bryony Simmons[SUP] 10 [/SUP], Andrew Hill[SUP] 11 [/SUP], Hafez Tirgar Fakheri[SUP] 12 [/SUP]
Affiliations
- PMID: 32812025
- DOI: 10.1093/jac/dkaa332
Abstract
Background: New therapeutic options are urgently needed to tackle the novel coronavirus disease 2019 (COVID-19). Repurposing existing pharmaceuticals provides an immediate treatment opportunity. We assessed the efficacy of sofosbuvir and daclatasvir with ribavirin for treating patients with COVID-19.
Methods: This was a single-centre, randomized controlled trial in adults with moderate COVID-19 admitted to the Ghaem Shahr Razi Hospital in Mazandaran Province, Iran. Patients were randomly assigned to 400 mg sofosbuvir, 60 mg daclatasvir and 1200 mg ribavirin (intervention group) or to standard care (control group). The primary endpoint of this study was length of hospital stay. This study is registered by IRCT.ir under the ID: IRCT20200328046886N1.
Results: Between 20 March 2020 and 8 April 2020, 48 patients were recruited; 24 patients were randomly assigned to the intervention group and 24 to the control group. The median duration of hospital stay was 6 days in both groups (P = 0.398). The number of ICU admissions in the sofosbuvir/daclatasvir/ribavirin group was not significantly lower than the control group (0 versus 4, P = 0.109). There was no difference in the number of deaths between the groups (0 versus 3, P = 0.234). The cumulative incidence of recovery was higher in the sofosbuvir/daclatasvir/ribavirin arm (Gray's P = 0.033).
Conclusions: This randomized trial was too small to make definitive conclusions. There were trends in favour of the sofosbuvir/daclatasvir/ribavirin arm for recovery and lower death rates. However, there was an imbalance in the baseline characteristics between the arms. Larger randomized trials should be conducted to investigate this treatment further.